Compare McKesson Corporation (MCK) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs NIO Inc. — how do they compare? McKesson Corporation trades at $828.8 (market cap $97.35B), while NIO Inc. trades at $4.89 (market cap $12.55B). The key difference: McKesson Corporation is far larger — about 7.8× NIO Inc.'s market cap, and McKesson Corporation pays a 0.39% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| MCK | NIO | |
|---|---|---|
Market Cap | $97.35B | $12.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $7.89 |
52-Week Low | $659.01 | $4.44 |
Enterprise Value | $101.98B | $11.78B |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
NIO trades at $4.83, down 1.02% on the day, with a bearish technical signal from moving averages. Revenue grew to $87.49B in 2025, but the company posted a net loss of $15.57B, reflecting persistent profitability challenges. Recent news highlights strong Q2 2026 vehicle deliveries, up 49.4% year-over-year, and a Goldman Sachs upgrade to Buy with a $7 price target, suggesting potential upside.
The outlook remains mixed: delivery growth and analyst optimism contrast with deep losses and negative cash flow. Key risks include intense EV competition and reliance on financing. Investors should weigh the growth trajectory against the path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
